Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Harvard Business School
Johnson and Johnson
Boehringer Ingelheim
Express Scripts
Daiichi Sankyo
Federal Trade Commission

Generated: June 25, 2017

DrugPatentWatch Database Preview

Details for Patent: 6,593,336

« Back to Dashboard

Details for Patent: 6,593,336

Title: Methods for treating irritable bowel syndrome
Abstract:This invention relates to the use of 5-HT3 receptor antagonists in the treatment of nonconstipated female IBS patients.
Inventor(s): Mangel; Allen Wayne (Chapel Hill, NC), Northcutt; Allison Ruth (Raleigh, NC)
Assignee: SmithKline Beecham Corporation (Philadelphia, PA)
Filing Date:Jun 10, 2002
Application Number:10/166,401
Claims:1. A method for improving bowel movement frequency in non-constipated female IBS which comprises administering an effective amount of a 5-HT.sub.3 receptor antagonist or a pharmaceutically acceptable derivative thereof.

2. The method according to claim 1, wherein the 5-HT.sub.3 receptor antagonist is alosetron or a pharmaceutically acceptable derivative thereof.

3. The method according to claim 2, wherein alosetron is in the form of its hydrochloride.

4. The method according to claim 1, wherein the 5-HT.sub.3 receptor antagonist is selected from granisetron, azasetron, tropisetron, ramosetron, ondansetron, lerisetron, (R) zacopride, cilansetron, itasetron, indisetron and dolasetron.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

US Army
Harvard Business School
Federal Trade Commission
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:

Google Plus